Resultado de búsqueda
22 de may. de 2024 · Wed, May 22, 2024, 8:00 AM 3 min read. Pioneering researcher to reveal cutting-edge strategies for preventing and treating the leading cause of heart disease and stroke at the cardiometabolic ...
22 de may. de 2024 · Boca Raton, FL, May 22, 2024 (GLOBE NEWSWIRE) -- The Cardiometabolic Health Congress (CMHC) is proud to announce that one of the foremost authorities in atherosclerosis, Peter Libby, MD, will...
Hace 21 horas · Peter Libby, MD. Cardiovascular Specialist, Brigham and Women's Hospital Mallinckrodt Professor of Medicine, Harvard Medical School Boston, MA. Learn More. Disclosures. The following relevant financial relationships have been disclosed by faculty, and all have been mitigated by Pri-Med Institute.
26 de may. de 2024 · Clarify which patients are at high risk for a CV event and examine the vascular biology of CV risk, the benefits of treating risk factors, and ongoing clinical trials. Authors: Peter Libby, MD, Chair; David G. Harrison, MD; Marc A. Pfeffer, MD, PhD; George L. Bakris, MD. Log In to Start.
Hace 3 días · Dynamic natural components and morphological changes in nonculprit subclinical atherosclerosis in patients with acute coronary syndrome and mild chronic kidney disease at the 1-year follow-up and clinical significance at the 5-year follow-up. Jia-cong Nong , Wei You , Yi-fei Wang , Yi Xu, Tian Xu, Pei-na Meng, Xiang-qi Wu, Zhi-ming Wu,
20 de may. de 2024 · Background: Compared with thin-strut durable-polymer drug-eluting stents (DP-DES), ultrathin-strut biodegradable-polymer sirolimus-eluting stents (BP-SES) improve stent-related clinical outcomes in patients undergoing percutaneous coronary intervention (PCI).
15 de may. de 2024 · Harrington: People like Paul Ridker and Peter Libby have been talking about this for years. McConnell: Right. I worked closely with them when I was at Brigham and Women's Hospital.
